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Purpose: There are excellent arguments in favor of the preferential use of prosthetic 
grafts above the knee for the treatment of infrainguinal occlusive disease. This approach 
has been popularized on the basis of the seemingly acceptable results when using 
polytetrafluoroethylene (PTFE). However, inmany centers, knitted Dacron polyester has 
been used in these patients, and there are several studies that show equivalent and, in 
some, superior esults with Dacron when compared with PTFE. The purpose of this 
study was to examine these results in a definitive way. 
Methods: A randomized prospective trial in eight clinical academic enters in the United 
States and Canada was initiated in 1991. Two hundred forty-four patients eligible for 
such a study, by virtue of criteria extant in each institution at the time, were centrally 
randomized. They underwent placement of either a knitted Dacron polyester graft 
impregnated with collagen or a thin-wall expanded reenforced PTFE graft to the 
above-knee popliteal artery, usually from the common femoral artery. They were fre- 
quently observed by protocol for as long as 5 years by a physical examination noninvasive 
hemodynamic study, including duplex scanning in many instances. Continuing patency 
was noted, as were other potential adverse outcome vents. The data were analyzed by the 
log-rank test for cumulative patency and expressed as Kaplan-Meier curves. Data were 
further analyzed with a Cox proportional hazards model. 
Results: There were no differences in graft groups in demographic or comorbid factors. 
The procedural mortality rate was zero, and the morbidity rate was low (6.5%). The 
long-term patient survival rate was excellent (77% at 3 years). At the end of these years, 
no statistical significance inprimary or secondary patency rates was observed between the 
two grafts (primary patency rate, 62% -+ 14.4% for Dacron; 57% -+ 1525% for PTFE). No 
unexpected adverse outcomes on limb status were noted. Patency rates in both graft 
groups were inferior in patients who received small grafts (5 to 6 mm vs 7 to 8 mm; 
hazards ratio, 4.15) and younger (<65 years) smoking patients. 
Conclusions: The fact that these two prosthetic grafts performed in equivalent fashion in 
a controlled, well-conducted prospective study is not surprising in spite of the previous 
work that suggested differences. I f the preferential use of synthetic bypass grafts above 
the knee is to be used, it should be restricted to older nonsmokers with favorable 
anatomy. In that instance, the choice of graft material will depend on handling charac- 
teristics and cost. Above-knee prostheses should be only selectively used in younger, 
smoking patients, and graft size should be carefully considered in patients who undergo 
this operation. (J Vase Surg 1997;25:19-28.) 
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Femoropopliteal-tibial artery bypass grafting has 
been shown to be an effective form of treatment for 
infrainguinal artery occlusive disease in which pa- 
tients have either intermittent clandication or resting 
critical ischemia. The use of this surgical procedure 
has progressively increased over the past decades 
since its introduction i  the United States in 1954 by 
Linton at the Massachusetts General Hospital. 1Yet 
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the results of these treatments are imperfect, and 
numerous strategies have been developed to prolong 
the effective longevity of these surgical reconstruc- 
tions and their beneficial results. One such strategy 
that has developed considerable recent advocacy is 
the preferential selection of prosthetic grafts for 
above-knee popliteal artery bypass grafting. Ipsilat- 
eral saphenous vein grafts remain the current "gold 
standard" against which the other types of graft ma- 
terial must be compared, and it is the undisputed 
graft of choice when the distal anastomosis must be 
to the below-knee popliteal or the more distal tibio- 
peroneal arteries. 2-4 However, the patency results 
with polytetrafluoroethylene (PTFE) to the above- 
knee popliteal artery segment rival that of saphenous 
vein in some author's eries, s-s Although somewhat 
controversial, a number of surgeons have persua- 
sively argued that if the above-knee popliteal artery is 
anatomically suitable, a synthetic prosthesis hould 
be considered preferentially. 9-12 The rationale is that 
the majority of such grafts have good results. Fur- 
thermore, if a prosthesis i used first, the saphenous 
vein is then spared for later use in more distal proce- 
dures in the small number of patients who will ulti- 
mately need such a second procedure. 
The majority of the initial experiences with the 
preferential above-knee synthetic approach have 
been with PTFE. However, there are a number of 
surgeons who prefer and have used lmitted polyester 
(Dacron) in such procedures, and there are several 
series that show equivalent, or even superior, results 
with polyester as compared with PTFE? aqs Thus in 
1991 it was decided to study this interesting question 
with a multicenter prospective randomized trial with 
the expressed purpose to maximize the benefits to 
patients who receive preferential prostheses by an 
appropriate selection of graft material with possibly 
identified superior performance. 
METHODS 
A multicentered randomized prospective clinical 
trial was designed to test the hypothesis that colla- 
gen-impregnated knitted polyester velour (HMDV; 
Hemashield Microvel Double Velour, Meadox 
Medicals, Oakland, N.J.) and thin-walled expanded 
polytetraflnoroethylene (PTFE; W. L. Gore, Flag- 
staff, Ariz.) performed equally as a conduit from the 
common femoral to the above-knee popliteal artery. 
The study was conducted at the following institu- 
tions (with the number of patients enrolled in paren- 
theses): Hahneman University Hospital (63); Uni- 
versity of Rochester Medical Center (57); Norfolk 
Surgical Group (36); McGill University, Montreal 
(26); Massachusetts General Hospital (25); Monte- 
fiore Medical Center, New York (16); Ocshner 
Clinic (7); Baptist Hospital, Memphis (1). 
Patients with arteriographically demonstrated oc- 
clusions of the superficial femoral artery and reconsti- 
tution of the above-knee popliteal artery were 
eligible for inclusion provided that a prior femoro- 
popliteal bypass in the same leg had not  been per- 
formed. Patients were entered "preferentially", i.e. 
vein still present, or "obligatory", i.e. vein absent 
(coronary artery bypass graft, etc.), or unsuitable (as 
judged by the treating surgeon). Patients with prior 
grafts for the treatment of aortic or iliac artery disease 
were eligible. No concurrent adjunctive revascular- 
izations, with the exceptions of iliofemoral bypass or 
iliac angioplasty, were permitted. Patients were ran- 
domized centrally after eligibility was determined by 
the operating surgeon and informed consent ob- 
tained. The study protocol was approved by the in- 
stitutional review board at each of the participating 
centers. Standard emographic and comorbidity data 
were collected. Graft diameter and postoperative an- 
ticoagulation regimens were determined by the oper- 
ating surgeon on a case-by-case basis. 
Patients were seen by protocol in follow-up at 1 
month, 3 months, 6 months, 12 months, 18 months, 
2 years, 4 years, and whenever necessary. Patients 
with graft occlusion (as assessed using institutional 
criteria) were assigned into one of the above intervals 
at the time the occlusion was detected. Graft occlu- 
sion was determined by clinical and noninvasive x- 
amination as performed in each institution--usually 
Doppler pressures and plethysmography. The proto- 
col originally allowed for either a duplex scan or an 
ankle-brachial index to assess graft patency, but was 
amended to mandate both studies in March of 1994. 
Patients with no occlusion at the time of their last 
follow-up (censors) were also placed into an appro- 
priate time interval. Other censors included those 
who were lost to follow-up and those who died. Case 
forms were filled out by the local project coordinator 
and forwarded to Meadox Medicals. Site visits were 
made to each institution on a regular basis by Mea- 
dox Mcdicals personnel to monitor each center's 
compliance. Data were analyzed with SAS (version 
6.10) to compute estimated survivals, hazard rates 
over specified time intervals, and to generate the tests 
comparing the different groups as well as the propor- 
tional hazards assumptions. Standard error calcula- 
tions were performed as suggested by Peto and rec- 
ommended by the Society for Vascular Surgery 16 and 
by the SAS-Greenwood method. 17 
A preliminary analysis ought o identify any cat- 
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Table I. Complications of above-knee 
femoropopliteal procedures 
HMD V PTFE Total 
Complication n % n % n % 
Cardiac (all) 4 3.6 1 0.8 5 2.2 
Neurological (all) 0 0.0 0 0.0 0 0.0 
Venous (all) 0 0.0 1 0.8 1 0.4 
Wound morbidity 
Mild infection 3 2.7 5 4.2 8 3.5 
Moderate lymphocele 1 0.9 0 0.0 1 0.4 
Graft infection 3 2.7 2 1.7 5 2.2 
Graft infection is all five graft infections occurring in the study, 
rcgardless of  when they occurred uring follow-up. All the other 
complications here arc defined as procedural complications that 
occurred prior to discharge. 
egoric variable that exhibited some relationship to 
graft occlusion using a log-linear model. Three-way 
or higher other relationships were ruled out (p < 
0.2), and further screening using the SAS procedure 
CATMOD was based on relationships to occlusion, 
namely primary diagnosis and age. 
Primary diagnosis was classified into three cate- 
gories: (1) claudication with viable extremity; (2) 
ischemic rest pain; and (3) limb ischemia with major 
or minor loss threatened; and age was broken into 
two categories, less than 65 years and more than 65 
years. CATMOD determined that the following vari- 
ables were related to primary diagnosis: graft diame- 
ter, lipid status, and run-off. Age was related to gen- 
der, cardiac history, smoking, and hypertension. 
These stratified variables were then analyzed using 
the Cox proportional hazards model using the SAS 
procedure PHREG. 18 If any of these variables were 
found to significantly affect he risk of graft occlusion 
in this stratified Cox model analysis, then this effect 
will have been determined after having taken into 
account the effects of the stratifying variables diagno- 
sis and age. Data are presented in Kaplan-Meier plots 
and as hazards ratio. 
RESULTS 
Two hundred forty-four patients had been en- 
tered into the study at the time it was closed on 
February 1, 1996. Of thesc, sufficient data for 
analysis existed in 231 patients at the time of this 
writing, and it is on this group, with follow-up 
extending to March 15, 1996, that this paper is 
based. The patients wcre compared according to 
the 16 variables identified in the methods ection. 
Only graft type (PTFE or HMDV) was controlled 
by the randomization, but there were no differ- 
ences between the PTFE and HMDV patient 
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Fig. 1. Kaplan-Meier plot of primary patency data of 
HMDV and PTFE grafts hows no difference. 
groups in rcgard to the other demographic and 
patient-specific variables. The demographic har- 
acteristics and procedure outcomes were the same 
at all sites of investigation. 
Morbidity and mortality data. No patient in 
either graft group died in the first 30 days after the 
surgical procedure. Postoperative complications oc- 
curred in 6.5% of patients, and there were no differ- 
ences between the PTFE and HMDV groups. These 
complication rates were not unexpected nor different 
from the general results in this sort of patient popu- 
lation undergoing these procedures. The wound 
morbidity rate (infection, disruption, delayed heal- 
ing) overall was 3.9%, which included 3.5 % that were 
deemed "mild" and resolved on antibiotics alone. 
Nonetheless, this underscores the fact that all lower- 
extremity bypass procedures, even those as limited as 
these, havc some wound complications. 
Cardiac complications (arrhythmia, congestive 
heart failure, and myocardial infarction) occurred in 
2.2% of patients, and none was fatal before discharge. 
There were no neurologic omplications, and venous 
thromboembolic complications occurred in 0.4%. 
These data are shown in Table 1. Graft infection that 
occurred over the duration of the study is also dis- 
played. 
Long-term graft patency data. Cumulative pa- 
tency data were compared by log-rank test as de- 
scribed and graphically presented as Kaplan-Meier 
plots. The primary patency rate at 3 years was 58% in 
the PTFE patients, 62% in the HMDV patients, and 
60% overall (Fig. I). The primary assisted patency 
rate was not calculated because intervention before 
graft occlusion only rarely was performed. Secondary 
patency rates were also similar in both groups and 
was 88% at 1 year, 80% at 2 years, and 75% at 3 years 
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Fig. 2. Kaplan-Meier plot of secondary patency data of 
HMDV and PTFE grafts shows no difference. 
in both groups (Fig. 2). There was no statistically 
significant difference in patency rates for up to 3 years 
between the PTFE and HMDV recipients. The 
complete 1-year, 2-year, and 3-year primary pa- 
tency data aregiven in Table II. Depending on the 
statistical method used (SAS-Greenwood or Peto), 
the standard error at 3 years was not or was greater 
than 10%. Although the confidence one places on 
these standard error methods varies from statistic 
to statistic, in light of  there only being 14 patients 
at risk at the end of  the third year, it is difficult to 
draw totally firm conclusions. On the other hand, 
the likelihood of  a change in conclusion is statisti- 
cally remote. The fact that in the Cox Hazards 
analysis there are also no differences i reassuring. 
Data were available for up to 3.2 years, and there 
was no difference in patient survival rates between 
the patient groups, with 77% overall surviving at 3 
years (Fig. 3). 
Impact o f  graft occlusion on limb status. 
Limb salvage rates are not highly~ relevant because 
the study included both claudication and critical 
ischemia patients. Limb salvage calculations, how- 
ever, did show similarity in both groups, at 94% to 
96% at 3 years as shown in Fig. 3. However, limb 
status after graft occlusion is an important determi- 
nant to evaluate because it might reflect possible 
adverse long-term impact of prosthesis failure, and 
these data were carefully examined. Fifty-five patients 
sustained at least one thrombotic occlusion (28 
PTFE and 27 HMDV). There were no noticeable 
differences in the mode of presentation of these 
events in the two prosthesis groups, and there was no 
difference in the incidence of adverse outcomes. The 
patients were treated in a variety of ways (thrombol- 
ysis, thrombectomy, redo bypass, and no treatment). 
SURVIVAL  . . . .  L IMB SALVAGE 
100 
80 
60 
40 
20 
0 
~ ' ' ~ - -  = . . . . . . . . . . .  ~ . . .=  . . . . . . . . .  ~ . . . . . .  .r 
" , L  & 
1 
[ I I I I I 
6 12 18 24 30 36 
MONTHS 
Fig. 3. Kaplan-Meier plot of patient survival and patient 
limb salvage data over the course of the study shows satis- 
factory results. 
Although nine patients in the series ultimately under- 
went major amputation, only one patient underwent 
major amputation (HMDV group) for advanced tis- 
sue necrosis in conjunction with prosthetic graft fail- 
ure. Other major amputations were in the presence 
of patent grafts because of  unmanageable local sep- 
sis/necrosis. 
Risk factors for graft occlusion. In spite of 
there being no differences in patency rates between 
the two different synthetic graft materials, a great 
deal was learned from the study as a whole, which 
analyzed the results of  a substantial group of patients 
who underwent above-knee femoropopliteai bypass 
operations in the modern era. There were 16 param- 
eters that potentially could have negatively impacted 
graft patency, and these were analyzed in a Cox 
proportional hazards model. The only risk factor for 
which the study was randomized and hence most 
rigorously controlled was graft type, and no differ- 
ences were observed for up to 3 years as already 
described. Of  the 15 additional variables, there was 
no effect on graft patency by primary diagnosis, dia- 
betes, hyperlipidemia, associated (cardiac, pulmo- 
nary, renal, and carotid) diseases, anatomic run-off, 
ankle-brachial indeK, ~ or right vs left leg. There were 
five risk factor variables that did impact on graft 
performance, and these were age, gender, smoking, 
hypertension, and, interestingly, graft diameter. 
In current practice, most surgeons would select a 
5 to 6 mm graft for femoropopliteal reconstruction, 
and no size was specified in the study protocol. Sev- 
eral investigators, however, used larger (7 to 8 mm) 
grafts. Surprisingly, the results show that the most 
powerful risk factor for graft occlusion was small 
graft diameter (p = 0.0006; hazards ratio, 4.15) 
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Tab le  I I ,  A .  Pr imary patency data, HMDV 
Time Patients Events 
interval at risk (occlusion) 
Withdrawn for cause 
Time LTF Death 
Interval 
patency 
rate 
Cumulative 
patency rate, 
% 
SE,% 
Greenwood Peto 
0 112 0 6 0 3 1.000 100.00 0.00 0.00 
1 103 2 9 2 2 0.979 100.00 0.00 0.00 
3 88 6 11 2 1 0.926 97.93 1.45 1.50 
6 68 11 8 3 1 0.823 90.67 3.15 3.36 
12 45 5 12 0 2 0.868 74.59 5.11 5.61 
18 26 1 8 0 0 0.955 64.77 6.03 7.54 
24 17 0 10 0 0 1.000 61.83 6.44 9.27 
36 7 2 5 0 0 0.556 61.83 6.44 14.44 
Totals 27 69 7 9 Grand total = 112 patients 
LTF, Lost to follow-up. 
Tab le  I I ,  B.  Pr imary patency data, PTFE  
Time Patients Events 
interval at risk (occlusion) 
Withdrawn for cause 
Time LTF Death 
Interval 
patency 
rate 
Cumulative 
patency 
rate, % 
SE,% 
Greenwood Peto 
0 119 4 
1 106 3 
3 93 7 
6 66 7 
12 49 2 
18 34 3 
24 24 2 
36 6 0 
Totals 28 
6 2 1 0.965 100.00 0.00 0.00 
10 0 0 0.970 96.51 1.72 1.75 
12 3 5 0.916 93.64 2.33 2.45 
5 4 1 0.885 85.74 3.57 3.99 
11 0 2 0.953 75.90 4.71 5.32 
7 0 0 0.902 72.33 5.12 6.53 
13 0 3 0.875 65.22 6.05 7.85 
6 0 0 1.000 57.06 7.55 15.27 
70 9 12 Grand total = 119 patients 
Tab le  I I ,  C.  Pr imary patency data, all grafts 
Withdrawn for cause 
Time Patients Events 
interval at r i sk  (occlusion) Time L TF Death 
Interval Cumulative 
patency patency 
rate rate, % 
SE,% 
Greenwood Peto 
0 231 4 12 2 4 
1 209 5 19 2 2 
3 181 13 23 5 6 
6 134 18 13 7 2 
12 94 7 23 0 4 
18 60 4 15 0 0 
24 41 2 23 0 3 
36 13 2 11 0 0 
Totals 55 139 16 21 
0.982 100.00 0.00 0.00 
0.975 98.20 0.89 0.91 
- 0.921 95.71 1.40 1.48 
0.854 88.13 2.40 2.62 
0.913 75.23 3.47 3.86 
0.924 68.69 3.96 4.96 
0.929 63.45 4.44 5.99 
0.733 58.82 5.15 10.47 
Grand total = 231 patients 
(Fig. 4). The  o ther  "risk factor"  variables were not  so 
powerfu l .  Both  young age (<65 years) and the pres- 
ence o f  smok ing  were associated w i th  a reduced 
patency rate (Fig. 5). I t  was not  possible to  sort  out  
the interre lat ionship,  but  it is possible to make the 
conc lus ion that  young ( < 6 5 years) smokers will have 
infer ior  results (hazards ratio, 1.85).  
Gender  and hyper tens ion  were also related. The  
data show that  men wi th  hyper tens ion  had an ident i -  
fiable improved  graft patency compared  wi th  both  
normotens ive  and female patients. This  associat ion is 
somewhat  difficult to explain in spite o f  its statistical 
occurrence (p < 0.05).  
D ISCUSSION 
The  hypothesis  o f  this study was that  impor tant  
differences wou ld  be found  between the patency per- 
formances  o f  above-knee femoropop l i tea l  bypass 
graft ing when us ing e i ther  o f  two  current ly popu lar  
synthetic graft materials: co l lagen- impregnated  knit- 
ted  polyester  (Dacron)  and re inforced expanded 
PTFE .  A l though that  d id not  prove to be the case, 
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Fig. 4. Kaplan-Meier plot shows graft patency data (both 
HMDV and PTFE groups comorbidity) inpatients receiv- 
ing 7 to 8 mm diameter vs 5 to 6 mm diameter grafts and 
shows superior results with larger grafts. 
this remains an important experience that provides 
useful general data about above-knee femoropopli- 
teal bypass reconstructions aggressively applied in the 
modern era. In fact, the results illustrate that this 
operation can be performed in an aged atheroscle- 
rotic patient population with considerable safety and 
generally acceptable results. No deaths, minimal 
complications, and a virtually absent adverse impact 
to patients on failure of treatment are all very positive 
features of the data analysis of this prospective expe- 
rience. 
Yet there is only roughly a 75% primary patency 
rate at the end of i year and 60% at 3 years. These 
data are somewhat troubling. When compared with 
the results of contemporary series of saphenous vein 
grafting, one might be tempted to generally con- 
clude that the results of  above-knee f moropopliteal 
bypass will be better with saphenous vein. 2,19 That 
temptation must be resisted because this conclusion 
can not  be drawn in the absence of a third arm of the 
study, i.e., saphenous vein grafts in randomization. 
Thepurpose of this randomized trial was to specifi- 
cally and only compare synthetic graft performance. 
This illustrates advantages/disadvantages of study 
design, while emphasizing the point that conclusions 
outside the design are not permissible. 
Nevertheless, one might still ask that because 
results represented seem generally and intuitively in- 
ferior to contemporary esults using saphenous vein, 
can the preferential use of synthetic bypass grafts be 
supported in the modern era? Those who promote 
this approach in their original argument state that 
even if the results may be somewhat inferior, they are 
not unacceptable and the majority of patients ustain 
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Fig. 5. Kaplan-Meier plot shows graft patency (both 
HMDV and PTFE groups comorbidity) in young (<65 
years) smoldng vs older nonsmoking patients and shows 
inferior esults in younger smokers. 
a satisfactory long-term result. Furthermore, the op- 
eration needed for prosthetic reconstruction is 
quicker with less-extensive incisions and dissection, 
and hence probably is associated with less morbidi- 
ty-especial ly wound complications as illustrated by 
this study as compared with the double-digit inci- 
dences reported for vein grafting by Reifsnyder et 
al. 2° Because both of those statements are undoubt- 
edly true, there will be considerable cost consider- 
ations involved. Cost factors were beyond the scope 
of this study, but is an analysis that needs to be done. 
The selection of statistical methods and interpre- 
tation of the results warrants further comment. De- 
pending on the method of statistical analysis used, 
the results at 3 years may or may not be deemed 
statistically significant in the "conventional" sense. 
The statistician for this project felt that the use of the 
standard error and its "cut off" of  greater than 10% 
rendering a black and white statistical validity to a 
conclusion is overemphasized. The statistical method 
of  SAS-Greenwood showed errors of less than 10%, 
which easily supports the conclusion that the results 
are valid at the 36-month mark. On the other hand, 
analysis by the method of Peto, that recommended 
in the reporting standards of the Joint Vascular Soci- 
eties, would suggest hat they are not, because thc 
errors are higher. The value of  additional and sup- 
portive statistical methods uch as the Cox propor- 
tional hazards analysis is very important and helpful 
in reconciling these differences. Although the sample 
size in the third year is small, nevertheless it seems 
reasonable to conclude that the results, which are 
clearly statistically valid by all criteria at 2 years, are 
similarly so and will remain similarly so at 3 years as 
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further time has passed. The hazards model, in 
fact, describes differences or lack thereof in the 
whole experience, not just at specific intervals. In 
this study, the risk of failure of a PTFE or a 
HMDV graft was the same over the whole time of 
follow-up. This exemplifies the merits, of course, 
of actuarial methods used to understand biologic 
phenomenon and trends. However, there are some 
puzzling aspects to the data, as well. Why males 
with hypertension have a superior esult certainly 
remains an unresolved issue. 
The equivalent patency results experienced by the 
two graft types are perhaps omewhat unexpected. 
The base polymers used in the fabrication of these 
two grafts are very different chemically, and the grafts 
are substantially different physically in construction. 
There are also significant differences in resulting tis- 
sue incorporation and pseudointima accumulation. 
One might thus expect performance differences such 
as reported by some workers. 6,14 Nevertheless, the 
results do support work of other investigators. 
Rosenthal et al.,~3 in a randomized personal series, 
showed that the results were equivalent. On the 
other hand, they are distinctly different from the 
retrospective study reported by one of the study 
investigators, which shows that the results up to 10 
years clearly supported the selective use of knitted 
Dacron. is However, the knitted Dacron grafts used 
in the retrospective study were different from those 
used in the current rial. One difference was a high 
porosity in the former (roughly 4000 ml per sq cm 
per minute) versus zero porosity in the latter because 
of the collagen impregnation. Another difference is 
the velour texture and, of course, the collagen on the 
surfaces and in the interstices of HMDV. Whether 
those differences are important remains to be seen 
because there is still a great deal about the biologic 
function of synthetic grafts after implantation that is 
not well understood. 
Certainly, one of the most interesting and possi- 
bly important findings in this study is in regard to the 
data illustrating the difference in patency rates be- 
tween grafts of larger (7 to 8 ram) versus maller (5 
to 6 mm) diameter. Further analysis will be needed 
to better understand this result, but the fact that the 
large-caliber prosthetic grafts performed in superior 
fashion is an important lesson. On the basis of this 
information, the surgeon should consider that if an 
above-knee femoropopliteal bypass graft using a 
prosthesis i  the treatment of choice, a larger-sized 
graft should be selected. 
The second-strongest risk factor for occlusion in 
this study was that of cigarette smoking. This im- 
pacted largely in younger patients, but younger pa- 
tients had a higher incidence of smoking, and these 
two risk factors impacted together in a covariable 
fashion. This leads to the conclusion that the worst 
results in above-knee prosthetic reconstructions 
would be expected in patients less than 65 years of 
age who are still actively smoking. It could be argued 
that such patients with intermittent claudication 
alone should not be operated on at all, and those 
with critical ischemia might be better served by sa- 
phenous vein grafting to an appropriate below-knee 
arterial segment. In fact, this seems intuitive by virtue 
of the fact that the younger patient will tend to have 
a longer life expectancy, and hence the greatest dura- 
bility of the reconstruction might b E desirable. 
The results reported here were also somewhat 
inferior to some highly selected series in which re- 
suits in above-knee femoropopliteal bypass with 
prosthetic grafts were better, 7,21 although they were 
very similar to others. ~,1° The investigators thus 
questioned whether patient selection might have 
been too liberal. Although that may well be the case, 
this study is actually atrue test of the preferential use 
of prostheses in the above-knee position because all 
patients in each institution were carefully evaluated 
for the suitability for above-knee bypass graft and 
then a prosthetic bypass was selected by virtue of 
participation i the study. Yet this does suggest that 
because the results were not as satisfactory as some 
workers might have anticipated that very careful se- 
lection of patients for above-knee operations in gen- 
eral should continue to be exercised. The investiga- 
tors considered another look at the arteriographic 
studies to confirm the suitability of the above-knee 
segment as a recipient vessel for a bypass graft. How- 
ever, by design, this was meant to be a relatively 
unselected, but aggressive use of prosthetic grafting. 
Thus further evaluation was not needed or justified 
because the results reflect an accurate description of a 
wide experience. 
In light of the results, the lack of adverse out- 
comes to the affected legs in patients in whom grafts 
had occluded is reassuring. Others have noted less 
satisfactory esults in patients after prosthetic grafting 
as compared to vein grafting. 19 That result was not 
observed herein and confirms older work by other 
investigators. 22 
CONCLUSION 
Two different commercially available prosthetic 
grafts performed in an equivalent fashion in a con- 
trolled, vigorously analyzed, carefully conducted 
prospective randomized trial. This result is not terri- 
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bly surprising, in spite o f  previous work that has 
suggested that there may be differences. The data 
imply that i f  the preferential use o f  prosthetic bypass 
grafts above the knee is to be used, this practice 
should be restricted to older nonsmokers with favor- 
able arterial anatomy (anastomotic site and run-off). 
In that particular instance, the choice o f  the graft 
material will depend on handling characteristics, costs, 
and other subjective features. In addition, the data 
strongly suggest that larger (7 to 8 mm diameter) 
grafts should be used. Finally, the data need to be 
considered in the broader perspective o f  the results 
using other strategies, including cost implications. 
We express our appreciation to Michael Miller, PhD, 
for his important contributions by virtue of statistical nal- 
ysis and interpretation. Also, the work and support of 
David Munjal, PhD, Susan Daum, Maryann Ackerman, 
and Doranne Porter at Meadox Medicals is acknowledged 
as essential to the completion of this study. 
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DISCUSSION 
Dr. Wesley S. Moore (Los Angeles, Calif.). Dr. Ab- 
bott and his colleagues have performed a prospective ran- 
domized multicenter t ial to determine whether there is 
any difference in the patency rates between e-PTFE and 
collagen-impregnated knitted polyester velour Dacron 
grafts when used in the femoral-to-above-knee popliteal 
bypass position. Two hundred forty-five patients were ran- 
domized, and data were complete for analysis in 231. The 
perioperative mortality rate was a remarkable 0%, and the 
incidence of major complications was quite low, which 
reaffirms the tolerance of high-risk patients to prosthetic 
bypass procedures. 
At 36 months, the primary patency rate was not statis- 
tically different: 58% for e-PTFE and 62% for Dacron. The 
secondary patency rate was 75% for both graft types. This 
brings me to the first question for the authors: are you 
planning to continue to observe these patients out to 5 
years? In the prospective randomized trial that compared 
PTFE with saphenous vein, there was no difference be- 
tween the two graft types during the first phase of observa- 
tion. It was only with later follow-up that a benefit devel- 
oped in favor of saphenous vein, and this was not readily 
apparent until 5 years. 
Fifty-five patients (28 PTFE and 27 Dacron) had at 
least one thrombotic event, which was reopened by a 
variety of techniques. My second question for the authors 
is: how many of these patients were then treated with 
warfarin to achieve the respectable 75% secondary patency 
rate? If this appears to be an important factor for achieving 
secondary patency, should we consider the routine use of 
warfarin in all patients who undergo prosthetic femoro- 
popliteal bypass procedures? 
The major risk factor that appeared to influence graft 
patency rates was graft diameter. Larger-diameter g afts 
were reported to do better than small-diameter grafts, with 
the difference being highly statistically significant (p = 
0.0006). This then leads me to my final questions for the 
authors. Was this graft size difference more a reflection of 
recipient arterial size than of the graft size? For example, 
women who also did less well than men would be more 
likely to have smaller popliteal arteries and perhaps would 
have received smaller grafts. In addition, was this difference 
true for both PTFE and Dacron when analyzed separately 
rather than analyzed in aggregate? Have you tried compar- 
ing patients who have had 6.0 mm PTFE and 8.0 mm 
Dacron as one group, against those who had other differ- 
ent graft sizes? I suspect that the optimum graft type may 
be different for the two prosthetic types. 
This manuscript is extremely well-written and well- 
analyzed, and it deserves our serious attention. 
Dr. William M. Abbott. Thank you, Dr. Moore, for 
your comments. This work could be considered perhaps in 
a somewhat controversial category, and I am very apprecia- 
tive that you have looked at it as carefully as you have. First, 
we analyzed all of the patency information for the only 
variable for which it was randomized, that is, the PTFE 
versus the HMDV. When we found no difference between 
those groups in every analysis, we believed that it was 
reasonable to lump the two together to get a better under- 
standing regarding what the impact of the operation was. 
The graft size data is also extremely intriguing to me, 
and my interpretation f them is that we ought to look 
carefully at the size of the arteries in making raft selection 
rather than picking size across the board. We did not 
actually analyze the data in this way, although these are 
secondary efforts that we will do to try to correlate that 
with the female versus male patients. Forty percent of the 
patients were female, so there are probably enough data 
there for us to make some sort of a conclusion. 
The question about anticoagulation is also a very good 
one, and we do not have accurate data on that. However, 
that is something I think that we can also look at. It was 
not specified, as I mentioned, whether anticoagulation was 
to be used or not to be used. Some patients received it and 
some did not. Further analysis will be necessary to answer 
that very important question. 
Finally, your question about whether we are going to 
extend the follow-up to 5 years. Absolutely. When this trial 
was initiated, we recognized, as you pointed out, the im- 
portance of the fact that although 3years is 3 years, it may 
not show much difference. However, over a longer course 
of time such differences may become apparent. So the 
study was set up and is planned to be carried out to a 
statistically significant fashion at the 5-year mark. 
Dr. Richard H. Dean (Winston-Salem, N.C.). Bill, I 
can't help but to ask this, being an unreformed ex-smoker. 
You showed that young smokers did worse than old smok- 
ers. I wonder whether you looked at the data to show 
whether old smokers did as well, better, or worse than old 
nonsmokers, being that getting to the age of 65 might be 
fun if you showed us that they did just as well as the 
nonsmokers. 
Dr. Abbott. This is true confessions time up here, 
Dick. I 'm quite surprised to hear you admit to us this 
smoking history of yours. ' In actual fact, it is impossible 
from a data set such as this to sort that out. The suggestion 
is that smoking is actually the more powerful of the two 
variables, but it is not possible to prove that from the data 
set that we have. 
Dr. Jack L. Cronenwett (Lebanon, N.H.). To follow 
up on the question about age, I was curious as to whether 
the explanation for lower patency rates in the younger 
patients was because they had longer follow-up, presum- 
ably because of greater life expectancy. Did you include 
length of follow-up in your multivariate analysis, and did 
the young patients really have worse function or just better 
follow-up? 
Dr. Abbott. I think that the answer to that excellent 
question isreally, again, not able to be forthcoming. Three 
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years isn't a very long time and further follow-up may show 
something. 
Dr. Stefan Carter (Winnipeg, Manitoba, Canada). In 
your abstract I read that in addition to young smokers 
having inferior results, you mentioned a reduced ankle- 
brachial index. I wasn't quite clear what you meant by that. 
Second, there were patients who had surgery for limb 
salvage and others for claudication. Were the results com- 
parable in these two groups? 
Dr. Abbott. The abstract is a little bit misleading. It
was the first data analysis, in which the risk stratification 
suggested that both anlde-brachial ndex and indication for 
operation may have a significant impact. However, on the 
secondary analysis that fell out, and that's why it was not 
mentioned in my presentation. 
Dr. Roger M. Greenhalgh (London, United King- 
dora). I am constantly amazed that in the United States it 
is possible to rely on the history of patients as far as 
smoking is concerned, as we have just heard from Dr. 
Dean. In Britain, I would have to say that our patients tend 
to be very economical with the truth, and we have to 
measure smoking by marker. When we do that, whether 
the patient is young or old, we get an absolute correlation 
with the failure of bypass procedures in those who smoke, 
by marker, be it carboxyhemoglobin or cotinine. 
Dr. Thomas F. O'Donnel l  (Boston, Mass.). Cer- 
tainly, there is initial up-front cost for the graft material. I 
wonder from your anecdotal experience with synthetic 
materials when compared with your experience with au- 
togenous vein, whether the low morbidity rate observed 
with synthetic grafts translates into an advantage in low- 
ered resource utilization. In addition, would you comment 
on the operating room time comparing synthetic grafts 
versus vein. If both the operating room time and the 
wound morbidity rates were markedly less with synthetic 
grafts while preserving the same patency rate, there would 
be an economic drive to use this as an initial strategy. 
Dr. Abbott. Tom, I thank you for that question. It is 
an extremely important question as we are all becoming 
more focused on the cost aspects. These operations aver- 
aged, at least at my own institution, about 90 minutes. The 
incisions are minimal, and the patients were going home 
on the second or third day after surgery unless they had 
necrotic problems in the foot that required other manage- 
ment. So I cannot help but believe, although we do not 
have the data, that there is going to be a very strong 
cost/benefit, at least up front. This is something that we 
really are going to look at, and I 'm sure Dr. Goldstone will 
be happy about hat. 
In conclusion, the Society of Vascular Surgery has 
come a long way in 50 years, and I think, as wimessed by 
what's going on here today, has achieved major accom- 
plishments in furthering our understanding of and our 
management of patients who have complex vascular disor- 
• ders. I personally feel privileged to have been part of that in 
the 20 years that I have been a member of this Society. 
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